Xiaojun Yan, MD
Pulmonary Disease · Brooklyn, NYNPI 1033110788
Payments from drug & device makers
Across 901 payments — averaging $276.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$111K
- AstraZeneca$64K
- Boehringer Ingelheim$48K
- Insmed, Inc.$13K
- Sunovion Pharmaceuticals Inc.$8K
- Sanofi$1K
- plus $5K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 181 | $110,823 |
| AstraZeneca | 209 | $63,876 |
| Boehringer Ingelheim | 151 | $47,849 |
| Insmed, Inc. | 53 | $12,599 |
| Sunovion Pharmaceuticals Inc. | 36 | $7,902 |
| Sanofi | 41 | $1,142 |
| Genentech USA, Inc. | 56 | $751 |
| Regeneron Healthcare Solutions, Inc. | 18 | $652 |
| Mylan Specialty L.p. | 25 | $541 |
| Philips North America LLC | 22 | $501 |
| Actelion Pharmaceuticals US, Inc. | 14 | $455 |
| Regeneron | 3 | $361 |
| Advanced Respiratory, Inc | 13 | $308 |
| Grifols USA, LLC | 16 | $263 |
| Inogen, Inc. | 13 | $256 |
| Mallinckrodt Hospital Products Inc. | 7 | $178 |
| ANI Pharmaceuticals, Inc. | 5 | $156 |
| Baxter Healthcare | 5 | $121 |
| Amgen(2 entities) | 5 | $107 |
| Paratek Pharmaceuticals, Inc. | 5 | $88 |
| Teva Pharmaceuticals USA, Inc. | 5 | $81 |
| Electromed, Inc. | 3 | $72 |
| Novartis | 4 | $60 |
| Pfizer | 3 | $52 |
| Optinose US, Inc. | 2 | $45 |
| Circassia Inc. | 1 | $28 |
| Viatris Specialty LLC | 1 | $28 |
| Verona Pharma, Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| United Therapeutics Corporation | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $18 |
How this compares
$249,376 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Brooklyn
- Ali El AtatBrooklyn$547K
- Sunil MehraBrooklyn$388K
- Aaliya BurzaBrooklyn$334K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.